Cephalon plans Phase III trial of Nuvigil in bipolar disorder
This article was originally published in Scrip
Executive Summary
Cephalonsays it is plans to initiate Phase III trials of its psychostimulant Nuvigil (armodafinil; R-modafinil), as an adjunctive therapy for treating major depressive disorder in adults with bipolar I disorder after it showed efficacy in Phase II.